Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes

Pegylated liposomal doxorubicin (PL-DOX or Doxil(R)) is currently being use d in the clinic to treat solid tumors in humans (ovarian and breast cancer and Kaposi's sarcoma). Previous preclinical studies comparing the antitumor activity of nonliposomal doxorubicin and PL-DOX have shown that PL-DOX has significantly greater antitumor activity at equivalent doses, but these st udies have not reported the degree of increase in antitumor potency associa ted with liposome encapsulation at lower doses of PL-DOX. The studies prese nted here were designed to determine the dose of PL-DOX that produces the s ame antitumor activity as the maximum tolerated dose (MTD) of nonliposomal doxorubicin. Conventional mice were inoculated with Lewis lung or C26 colon cells, and nude mice were inoculated with BT474 or MCF7 human breast cance r cells. Tumor-bearing mice were treated with nonliposomal doxorubicin at t he MTD or with PL-DOX at the same or lower doses. As in previously publishe d studies, PL-DOX had significantly greater antitumor activity than nonlipo somal doxorubicin at the same dose levels (p < 0.05). In Lewis Lung and C26 Colon carcinoma, antitumor activity of nonliposomal doxorubicin (9 mg/kg, the MTD for conventional mice) was equivalent to antitumor activity of PL-D OX at 2 mg/kg, a 4.5-fold increase in antitumor potency. In human breast ca ncer xenografts (BT474 and MCF7) in nude mice, antitumor activity of nonlip osomal doxorubicin (4 mg/kg, the MTD for nude mice) was equivalent to PL-DO X at 2 mg/kg, a 2-fold increase in potency. Based on results of these studi es, the potency of PL-DOX is increased from 2- to 4.5-fold compared to nonl iposomal doxorubicin.